Condition

HER2 + Breast Cancer

ClinicalTrials.gov condition label

Clinical trials23

Recruiting11

Common interventions25

Lead sponsors shown15

Clinical trials

23 shown

Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding StudyNCT07739511 · 2026-07-29

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast CancerNCT07600164 · 2026-07-06

Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast CancerNCT07695259 · 2026-05-25

A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast CancerNCT07294508 · 2026-02-27

Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast CancerNCT07393425 · 2026-02-02

Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast MalignanciesNCT07211178 · 2025-10-27

A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast CancerNCT07081555 · 2025-10-06

HER2-positive Breast Cancer RegistryNCT06603597 · 2024-09-27

A Phase 1/1b Study of IAM1363 in HER2 CancersNCT06253871 · 2024-03-25

RADIomics to Predict HER2 Status And T-DXd Efficacy in Metastatic Breast Cancer: the RADIOSPHER2 StudyNCT07030569 · 2024-02-01

RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II StudyNCT07065435 · 2024-01-01

A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer PatientsNCT07824869 · 2026-10-31

NOT_YET_RECRUITING

Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNCT07766772 · 2026-09-30

NOT_YET_RECRUITING

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast CancerNCT07601620 · 2026-07-03

NOT_YET_RECRUITING

Circulating Tumor DNA Dynamics to Optimize Neoadjuvant Therapy in HER2-Positive and Triple-Negative Breast CancerNCT07662252 · 2026-07-01

NOT_YET_RECRUITING

Exploratory Study of SHR-A1811 Via Different Administration Routes in PatientsNCT07560475 · 2026-06-10

NOT_YET_RECRUITING

Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and AbemaciclibNCT07428018 · 2026-04-30

NOT_YET_RECRUITING

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX87in Combination With HLX22 or Pertuzumab in the Neoadjuvant Therapy of HER2-Positive Bresat CancerNCT07294534 · 2026-01-27

NOT_YET_RECRUITING

SHR-A1811 for HER2-positive Breast Cancer With Suboptimal Neoadjuvant ResponseNCT07129187 · 2025-10-01

NOT_YET_RECRUITING

Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.NCT07136974 · 2025-09-01

NOT_YET_RECRUITING

A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast CancerNCT06878248 · 2025-04-17

Personalized Detection of ctDNA for Patients With HER2-Positive Metastatic Breast Cancer Patients Who Achieved Durable Response to Anti-HER2 TreatmentNCT06663787 · 2024-04-01

ACTIVE_NOT_RECRUITING

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric CancerNCT01598077 · 2012-07-01

Common interventions

Leading sponsors

Shanghai Henlius Biotech4 Affibody1 Calibr, a division of Scripps Research1 Chuan Wang1 Federico II University1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano1 Fujian Cancer Hospital1 Henan Cancer Hospital1 Iambic Therapeutics, Inc1 Liu Shu1 Mario Negri Institute for Pharmacological Research1 Nagoya City University1 Novartis Pharmaceuticals1 Peking University People's Hospital1 Priyanka Sharma1

Trial status mix

RECRUITING11

NOT_YET_RECRUITING9

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

Phase mix

PHASE211

PHASE16

PHASE32

PHASE42

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.